Evaluation of the effective time for GSK-3 inhibition in experimental autoimmune encephalomyelitis mouse model by tideglusib (NP-12) in preventing neuroinflammation
Glycogen synthase kinase-3 (GSK-3) is an enzyme involved in various neurodegenerative and neuro-inflammatory diseases, including multiple sclerosis (MS) and its animal model of experimental autoimmune encephalomyelitis (EAE). The severity of the disease could be characterized by the degree of cel...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2018
|
| Subjects: | |
| Online Access: | http://psasir.upm.edu.my/id/eprint/84211/1/FPSK%20%28m%29%202019%2033%20UPM%20ir.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Glycogen synthase kinase-3 (GSK-3) is an enzyme involved in various
neurodegenerative and neuro-inflammatory diseases, including multiple sclerosis
(MS) and its animal model of experimental autoimmune encephalomyelitis (EAE).
The severity of the disease could be characterized by the degree of cellular invasion
to the central nervous system (CNS) and demyelination that partly mediated by Th1
and Th17 effector cells. The present study is to investigate the efficacy of GSK-3
inhibition at a different course of treatment in ameliorating disease progression. This
study also aims to evaluate the effects of GSK-3 inhibition to central neuro-invasion
and demyelination. Female C57BL/6 mice were induced with myelin oligodendrocyte
glycoprotein (MOG35-55) in conjunction with complete freund's adjuvant (CFA) and
pertussis toxin. Inhibition of GSK-3 is performed by the administration of NP-12, a
small heterocyclic Thiadiazolidinones (TDZD), intraperitoneally during pre-EAE
induction, on the same day, and post-EAE. Data revealed that NP-12 delivery during
pre-EAE induction greatly protected the mice from EAE, delayed the onset of EAE
symptoms by 7 days from day-14.3 ± 0.5 (in EAE mice) until day-21.3 ± 3.2 (in the
treated mice). Furthermore, NP-12 treated-EAE mice had notably reduced the
inflammatory cells infiltration and axonal damage (demyelination) in the spinal cord.
Inhibition of GSK-3 also abrogated the production of Th1, Th9 and Th17 associated
cytokines but, increases the production of IL-4 level to 1790 ± 95.0 pg/mL compare
to EAE 480 ± 38.0 pg/mL and in IL-10 780 ± 22.0 pg/mL compared to EAE 410 ±
16.0 pg/mL. These data demonstrate the effectiveness of NP-12 at a different time
course of administration to reduce the severity of EAE disease and protect the CNS
environment from potential cellular invasion or demyelination, thus, suggests the
potential use of GSK-3 inhibitor in the treatment of EAE. |
|---|